A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients

NCT03485326 · clinicaltrials.gov ↗

COMPLETED

Status

1700

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Sponsor

AstraZeneca